Application of organic estrogenes in women from the tubal-peritoneal factor of infertility in the cycle of art
Keywords:infertility, implantation, pregnancy, endometrium, Proginova
The article discusses the advisability of using oral estrogens in the treatment of infertility in cycles of auxiliary reproductive technologies in women with a tubal peritoneal factor of infertility. The authors present their own observations and practical experience, which are based on a meta-analysis of global trends concerning the effect of oral estrogens on the state of the endometrium in conducting controlled ovarian stimulation.
Described study conduct additional inclusion in the drug supply of the ART program Proginova in a dose of 4 mg per day with the prolongation of the using until 12 weeks of pregnancy, with the purpose of pregnancy and its physiological prolongation in women with tubal peritoneal factor of infertility. The results which we have obtained showed the high effectiveness of the using preparation containing estrogens as a part of complex therapy during the cycles of auxiliary reproductive technologies. It was found that the use of estrogen preparations improved the implantation receptivity of the endometrium, achieved the necessary thickness of the endometrium, improved the pregravidary transformation of the endometrium, prolonged pregnancy, in the presence of the threat of interruption in the early periods (until 12 weeks).
At appendix of oral estrogens of the standard hormone therapy in the treatment of infertility by the methods of auxiliary reproductive technologies, the number of onset of biochemical pregnancies, the number of diagnosed clinical pregnancies which were diagnosed during ultrasound, and the number of pregnancies prolonged until the 12th week of pregnancy, significantly increased on comparison with the standard treatment without application of drugs which contain estrogen. All patients had noted the ease of using oral forms of estrogen preparations, the absence of side effects and the convenience of a prescribed hormone therapy regimen in the treatment of infertility.
Considering the significant positive effect from application preparation Proginova in the complex scheme of drug support of the program of auxiliary reproductive technologies the high expedience was marked in using it in ART programs as standard scheme pharmacological support of endometrial functionality and prolongation of pregnancy in a period until 12 weeks.
- Grishchenko, V.I., Shcherbina, N.A. “Female infertility: the state of the problem.” International Medical Journal 1 (2009): 89–92.
- Samoilova, A.V., Kostrova, E.V. “Receptor apparatus of endometrium in women of reproductive age with ovarian insufficiency.” Journal of Obstetrics and Women’s Diseases Vol. LVII.4 (2008): 103–7.
- Sharapova, O.V. “Modern problems of women’s reproductive health: ways to solve.” Questions of gynecology, obstetrics, perinatology 2.1 (2009): 7–10.
- Avramenko, N.V., Kabachenko, O.V., Maksimenko, V.G., Barkovskyi, D.E. “Influence of the state of expression of nuclear receptors of sex steroid hormones in the endometrium on woman reproductive function.” Zaporizhzhya Medical Journal 5 (2015): 66–8.
- Dakhno, F.V. “Use of micronized progesterone gel in IFV programs.” Woman’s Doctor 1 (2010): 16–19.
- Kotsabin, N.V., Makarchuk, O.M. “The role of the morphofunctional state of the endometrium as a leading factor in the successful implantation of the fertilized egg.” Archive of clinical medicine 2.20 (2014): 8–10.
- Giulmamedova, I.D., Dotsenko, O.S., Savchenko, I.V., Giulmamedova, O.A. “Modern views on the diagnosis and correction of implant receptivity of the endometrium (literature review).” Taurian medical and biological bulletin 16.2 Part 2 (62) (2013): 169–74.
How to Cite
Copyright (c) 2017 В. В. Камінський, М. Н. Шалько, І. В. Малишева, Ю. С. Мудра
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.